Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment

Journal of Clinical Medicine
Akira NakaoKoichi Takayama

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and efficacy in older patients. This phase II trial (jRCTs071180002) evaluated osimertinib in T790M mutation-positive Japanese patients who were ≥75 years old and had experienced relapse or progression after previous EGFR-TKI treatment. Our previous report that enrolled 36 patients showed the overall response rate (58.3%) and disease control rate (97.2%), while this report describes the results for the progression-free survival (PFS), overall survival (OS), and safety analyses. The median PFS was 11.9 months (95% confidence interval (CI): 7.9-17.5), and the median OS was 22.0 months (95% CI: 16.0 months-not reached). The most frequent adverse events were anemia/hypoalbuminemia (27 patients, 75.0%), thrombocytopenia (21 patients, 58.3%), and paronychia/anorexia/diarrhea/neutropenia (15 patients, 41.7%). Pneumonitis was observed in four patients (11.1%), including two patients (5.6%) with Grade 3-4 pneumonitis. These results suggest that o...Continue Reading

References

Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shinzoh KudohMasahiro Fukuoka
Mar 14, 2008·American Journal of Respiratory and Critical Care Medicine·Shoji KudohFredrik Nyberg
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Mar 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helena A YuGregory J Riely
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Dec 17, 2015·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Lindsey A TorreAhmedin Jemal
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
Feb 22, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James Chih-Hsin YangPasi A Jänne
Apr 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L Paz-AresK Park
Oct 11, 2017·Clinics in Geriatric Medicine·Julie A BartaMichael Unger
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators
Dec 7, 2018·Japanese Journal of Clinical Oncology·Yuichiro OheKazuhiko Nakagawa
Nov 22, 2019·The New England Journal of Medicine·Suresh S RamalingamUNKNOWN FLAURA Investigators

❮ Previous
Next ❯

Citations

Feb 18, 2021·Expert Opinion on Pharmacotherapy·Luigi CerboneCarlo Genova
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolò Matteo Luca BattistiAlistair Ring

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.